GSK said it is ending the development program for the small-molecule drug Belrestotug. The British pharmaceutical giant said Tuesday that the decision is based on a new interim analyses from phase ...

Glycans are notoriously difficult to tag with any kind of probe, because unlike proteins or DNA ... This chemical group presented an opportunity to use a small-molecule tag that had been previously ...

Partnership will leverage OpenBench’s AI-enabled screening platform to complement 858’s early discovery efforts – SAN DIEGO & SAN FRANCISCO--(BUSINESS WIRE)--858 Therapeutics and OpenBench today ...

Experts from the University of of Dundee's Centre for Targeted Protein Degradation (CeTPD), working with Boehringer Ingelheim scientists, have developed a breakthrough small-molecule drug ...

but show a bright fluorescent glow when treated with (S)-PHA533533, indicating that the small molecule potently activated the dormant paternal allele of UBE3A. [Vihma et. al 2024] Researchers were ...

"We still have a lot of work to do before we could start a clinical trial, but this small molecule provides an excellent starting point for developing a safe and effective treatment for Angelman ...

Researchers have now found a new small molecule that restores telomerase levels and reverses hallmarks of aging in elderly mice. One of the main components of telomerase is a donut-shaped protein ...

The modulation of RNA splicing by small molecules has emerged as a promising strategy for treating pathogenic infections, human genetic diseases, and cancer; however, the principles by which ...

Please provide your email address to receive an email when new articles are posted on . EXN407 met primary endpoints of safety and tolerability and also demonstrated decreases in vascular leakage ...

A485 is a small molecule — colloquially known as “prohiberin” — that inhibits proteins that modulate gene expression. The researchers hope that the discovery could help human patients with neutropenia ...

In a recent study published in Scientific Reports, researchers described the preclinical profile of JT002, a novel and orally bioavailable small molecule inhibitor of the NLR family pyrin domain ...